Pump Thrombosis following HeartMate II Left Ventricular Assist Device Implantation in a Patient with Aspirin and Plavix Resistance

  • Ali Ghodsizad Heart and Vascular Institute, Penn State Milton S. Hershey Medical Center, Penn State College of Medicine, Hershey, Pennsylvania
  • A. Badiye Miami Transplant Institute, University of Miami, Jackson Memorial Hospital, Miami, Florida
  • M. Zeriouh Nazih Zuhdi Transplant and Advanced Cardiac Care Institute, INTEGRIS Baptist Medical Center, Oklahoma City, Oklahoma
  • W. Pae Heart and Vascular Institute, Penn State Milton S. Hershey Medical Center, Penn State College of Medicine, Hershey, Pennsylvania
  • M.M. Koerner Heart and Vascular Institute, Penn State Milton S. Hershey Medical Center, Penn State College of Medicine, Hershey, Pennsylvania
  • M. Loebe Heart and Vascular Institute, Penn State Milton S. Hershey Medical Center, Penn State College of Medicine, Hershey, Pennsylvania

Abstract

Despite advances in pump technology, thromboembolic events and pump thrombosis are potentially life-threatening complications in patients with continuous flow ventricular assist devices. Here we describe a patient with pump thrombosis following LVAD HeartMate II implantation presenting with Aspirin and Plavix resistance and signs of acute hemolysis as manifested by high LDH, changing pump power, pulse index and reduced pump flows.

References

Birschmann I, Dittrich M, Eller T, et al. 2014. Ambient hemolysis and activation of coagulation is different between HeartMate II and HeartWare left ventricular assist devices. J Heart Lung Transplant 33:80-7.

Hasin T, Deo S, Maleszewski JJ, et al. 2014. The role of medical management for acute intravascular hemolysis in patients supported on axial flow LVAD. ASAIO J 60:9-14.

Katz JN, Jensen BC, Chang PP, et al. 2015. A multicenter analysis of clinical hemolysis in patients supported with durable, long-term left ventricular assist device therapy. J Heart Lung Transplant 34:701-9.

Published
2016-12-14
Section
Articles